Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6440)
All Articles published online
|
Publishing Process of This Article
|
Feb 27, 2023 (publication date) through Nov 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kram M. Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis. World J Hepatol 2023; 15(2): 201-207 [PMID: 36926236 DOI: 10.4254/wjh.v15.i2.201] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v15/i2/201.htm |
| Number | Citing Articles |
| 1 |
Anna Lisa Cammarota, Antonia Falco, Anna Basile, Carlo Molino, Massimiliano Chetta, Gianni D’Angelo, Liberato Marzullo, Margot De Marco, Maria Caterina Turco, Alessandra Rosati. Pancreatic Cancer-Secreted Proteins: Targeting Their Functions in Tumor Microenvironment. Cancers 2023; 15(19): 4825 doi: 10.3390/cancers15194825
|
| 2 |
Michail Kokkorakis, Emir Muzurović, Špela Volčanšek, Marlene Chakhtoura, Michael A. Hill, Dimitri P. Mikhailidis, Christos S. Mantzoros, Ali Eid. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies. Pharmacological Reviews 2024; 76(3): 454 doi: 10.1124/pharmrev.123.001087
|
| 3 |
Shifang Tang, Jürgen Borlak. Genomics of human NAFLD: Lack of data reproducibility and high interpatient variability in drug target expression as major causes of drug failures. Hepatology 2024; 80(4): 901 doi: 10.1097/HEP.0000000000000780
|
| 4 |
Praveenkumar Shetty, Pavan K. Jayaswamy, Prakash Patil, M. Vijaykrishnaraj, Jamboor K. Vishwanatha, Sukanya Shetty. Cardiometabolic Diseases. 2025; : 159 doi: 10.1016/B978-0-323-95469-3.00029-2
|
| 5 |
Paolo Comeglio, Giulia Guarnieri, Sandra Filippi, Ilaria Cellai, Gabriele Acciai, Ian Holyer, Fredrik Zetterberg, Hakon Leffler, Barbro Kahl-Knutson, Erica Sarchielli, Annamaria Morelli, Mario Maggi, Robert J. Slack, Linda Vignozzi. The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1430109
|
| 6 |
Angeliki Katsarou, Georgios Tsioulos, Eva Kassi, Antonios Chatzigeorgiou. Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease. Hormones 2024; 23(4): 621 doi: 10.1007/s42000-024-00588-1
|
| 7 |
Yasmin Mohtasham Kia, Alessandro Cannavo, Pegah Bahiraie, Sanam Alilou, Behrad Saeedian, Nastaran Babajani, Elina Ghondaghsaz, Amirmohammad Khalaji, Amir Hossein Behnoush, Sowjanya Thatikonda. Insights into the Role of Galectin-3 as a Diagnostic and Prognostic Biomarker of Atrial Fibrillation. Disease Markers 2023; 2023: 1 doi: 10.1155/2023/2097012
|
| 8 |
Jorge Arnold, Francisco Idalsoaga, Luis Antonio Díaz, Daniel Cabrera, Francisco Barrera, Juan Pablo Arab, Marco Arrese. Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon. Current Hepatology Reports 2024; 23(1): 204 doi: 10.1007/s11901-023-00629-0
|
| 9 |
Mohammadjavad Sotoudeheian. Galectin-3 and Severity of Liver Fibrosis in Metabolic
Dysfunction-Associated Fatty Liver Disease. Protein & Peptide Letters 2024; 31(4): 290 doi: 10.2174/0109298665301698240404061300
|